Scholarlink

Background <p>Late adverse reactions associated with the combined therapy of valproate and lamotrigine are infrequently documented within the Chinese population.</p> Case presentation <p>This case report describes a 54-year-old female patient who developed adverse reactions following long-term therapy with valproate and lamotrigine,&#xa0;with symptoms emerging five months after the final adjustment of her antiseizure regimen. The patient presented with symptoms of dizziness, ataxia, nystagmus, and postural tremors. Following blood drug concentration monitoring and subsequent minor dosage adjustments to the antiseizure regimen without medication withdrawal, the patient's symptoms were successfully resolved.</p> Conclusions <p>This article underscores the importance of vigilance among clinicians regarding the potential for late adverse reactions and advocates for the proactive monitoring of blood drug concentrations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Case report: late adverse reactions in an epilepsy patient on combination therapy with valproate and lamotrigine

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月30日

查看全文
  • Hui Sang,
  • liqiao Zhao,
  • Yanhua Zhang,
  • Xiaolong Wang,
  • Xiaodong Zhang

摘要

Background

Late adverse reactions associated with the combined therapy of valproate and lamotrigine are infrequently documented within the Chinese population.

Case presentation

This case report describes a 54-year-old female patient who developed adverse reactions following long-term therapy with valproate and lamotrigine, with symptoms emerging five months after the final adjustment of her antiseizure regimen. The patient presented with symptoms of dizziness, ataxia, nystagmus, and postural tremors. Following blood drug concentration monitoring and subsequent minor dosage adjustments to the antiseizure regimen without medication withdrawal, the patient's symptoms were successfully resolved.

Conclusions

This article underscores the importance of vigilance among clinicians regarding the potential for late adverse reactions and advocates for the proactive monitoring of blood drug concentrations.